Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Gastroenterology 8

Gastroenterology

recent-pharma-biotech-news-for-prolacta-renovia-magnus-hinge-health

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Magnus Medical’s tech gets breakthrough status; Prolacta develops tests for pathogens detection; Renovia gets breakthrough designation for leva system; Hinge Health secures $600M funding

Magnus Medical’s neurostimulation technology gets FDA breakthrough status to treat MDD Magnus Medical has secured a breakthrough device designation from the US Food and Drug Administration (FDA) for its neurostimulation technology for major depressive disorder (MDD) treatment. The individualised, rapid-acting, and non-invasive neurostimulation technology has been designed for MDD treatment in people who have not improved sufficiently from antidepressant medication or other treatments. Magnus Medical has also secured USD 25 Million under the Series A financing round co-led by JAZZ Venture Partners and Red Tree Venture Capital. The Magnus system is developed...

Explore More...

Hot flashes

Notizia

FDA

Copiktra receives approval; Lilly wins approval; Eisai’s Fycompa; Astellas’ Roxadustat; Janssen’s Esketamine Nasal Spray

Orchard files for IPO; J&J puts money on RNA interference; Rgenix receives $40M; GSK gives a helping hand

pancrea

Can GABA turn pancreatic α-cells into β-cells?

transthyretin amyloidosis

Notizia

astellas

Commercial Outcomes – Novartis

Takeda buys Shire in a deal worth USD 62 billion

Takeda acquisition on Shire raises its share by 25 percent

Business Cocktail

Novartis’s Entresto; AZ, J&J and Lilly sharply cut death rates; CAR-T drugs worth; FDA warns

Epidemiology: Fatty Liver Disease

Familial Adenomatous Polyposis (FAP): A cataclysmic genetic mutation

Microbiome- A Living Therapy from Guts to Cancer

Novartis eyes; Pfizer considers cashing; Mylan pushes to seal $465M; Valeant with Takeda for deal

Fresenius Kabi introduced Bivalirudin; Envigo Launches; Mylan’s MAA accepted; Pricing hit pharma

FDA Approves STELARA; Novartis announces AMG 334; AbbVie’s HCV Regimen; PaizaBio Gains CFDA Approval; WuXi Biologics completes construction

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly